Radnor Capital Management LLC Acquires Shares of 2,733 Gilead Sciences, Inc. (NASDAQ:GILD)

Radnor Capital Management LLC acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 2,733 shares of the biopharmaceutical company’s stock, valued at approximately $229,000.

Several other large investors have also recently made changes to their positions in GILD. Vanguard Group Inc. lifted its stake in shares of Gilead Sciences by 2.6% in the 1st quarter. Vanguard Group Inc. now owns 114,732,575 shares of the biopharmaceutical company’s stock valued at $8,404,161,000 after purchasing an additional 2,910,147 shares during the period. Swedbank AB acquired a new position in shares of Gilead Sciences in the 1st quarter valued at $134,489,000. International Assets Investment Management LLC lifted its stake in shares of Gilead Sciences by 8,238.4% in the 3rd quarter. International Assets Investment Management LLC now owns 1,642,504 shares of the biopharmaceutical company’s stock valued at $137,708,000 after purchasing an additional 1,622,806 shares during the period. Capital Research Global Investors lifted its stake in shares of Gilead Sciences by 2.7% in the 1st quarter. Capital Research Global Investors now owns 61,246,366 shares of the biopharmaceutical company’s stock valued at $4,486,296,000 after purchasing an additional 1,589,240 shares during the period. Finally, Pacer Advisors Inc. lifted its stake in shares of Gilead Sciences by 24.7% in the 2nd quarter. Pacer Advisors Inc. now owns 7,889,663 shares of the biopharmaceutical company’s stock valued at $541,310,000 after purchasing an additional 1,564,792 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms recently issued reports on GILD. Leerink Partners upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $74.00 to $96.00 in a research note on Monday, October 21st. Evercore ISI upgraded shares of Gilead Sciences to a “strong-buy” rating in a research report on Friday, August 9th. JPMorgan Chase & Co. upped their price objective on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research report on Thursday. Finally, Cantor Fitzgerald upped their price objective on shares of Gilead Sciences from $70.00 to $80.00 and gave the stock a “neutral” rating in a research report on Thursday. Eleven research analysts have rated the stock with a hold rating, eleven have issued a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $90.05.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total value of $167,660.00. Following the transaction, the insider now owns 100,189 shares of the company’s stock, valued at $8,398,843.87. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total value of $167,660.00. Following the transaction, the insider now owns 100,189 shares of the company’s stock, valued at $8,398,843.87. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Johanna Mercier sold 29,357 shares of the company’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the transaction, the insider now directly owns 78,127 shares in the company, valued at $6,545,480.06. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 62,437 shares of company stock valued at $5,374,825. 0.29% of the stock is owned by company insiders.

Gilead Sciences Trading Up 6.8 %

Shares of GILD opened at $97.90 on Friday. The company has a current ratio of 1.14, a quick ratio of 0.95 and a debt-to-equity ratio of 1.18. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $98.32. The firm has a 50-day moving average price of $84.58 and a 200 day moving average price of $74.67. The firm has a market capitalization of $121.88 billion, a P/E ratio of 119.39, a P/E/G ratio of 3.13 and a beta of 0.17.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. The firm had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. During the same quarter in the prior year, the firm posted $2.29 earnings per share. Gilead Sciences’s quarterly revenue was up 7.0% on a year-over-year basis. Sell-side analysts forecast that Gilead Sciences, Inc. will post 3.75 EPS for the current year.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.